NASDAQ:BIIB

Biogen Stock Forecast, Price & News

Most-Downgraded Stocks

$277.91

-2.38 (-0.85 %)

(As of 01/15/2021 12:39 PM ET)

Add

Compare

Today's Range

$277.17

Now: $277.91▼

$282.44

50-Day Range

$240.17

MA: $247.76▼

$267.52

52-Week Range

$223.25

Now: $277.91▼

$374.99

Volume59,995 shs

Average Volume1.41 million shs

Market Capitalization$42.77 billion

P/E Ratio9.20

Dividend YieldN/A

Beta0.53

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

2.10 out of 5 stars

Medical Sector

66th out of 1,480 stocks

Biological Products, Except Diagnostic Industry

4th out of 141 stocks

3.1 Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on 13 buy ratings, 15 hold ratings, and 5 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $306.13, Biogen has a forecasted upside of 10.1% from its current price of $278.11.
Amount of Analyst Coverage
Biogen has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Biogen has received 1,617 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biogen has received 1,082 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biogen has received 59.91% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote “Outperform” if you believe BIIB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have bought 42.49% more of their company's stock than they have sold. Specifically, they have bought $748,061.00 in company stock and sold $525,000.00 in company stock.
Percentage Held by Insiders
Only 0.54% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
83.51% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to decrease by -25.22% in the coming year, from $33.63 to $25.15 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 9.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 9.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 37.89.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:BIIB

Previous Symbol

CUSIP09062X10

CIK875045

Webwww.biogen.com

Phone617-679-2000

Employees7,400

Debt

Debt-to-Equity Ratio0.69

Current Ratio2.06

Quick Ratio1.79

Price-To-Earnings

Trailing P/E Ratio9.20

Forward P/E Ratio8.26

P/E Growth0.96

Sales & Book Value

Annual Sales$14.38 billion

Price / Sales2.97

Cash Flow$42.49 per share

Price / Cash Flow6.54

Book Value$73.93 per share

Price / Book3.76

Profitability

EPS (Most Recent Fiscal Year)$33.57

Net Income$5.89 billion

Net Margins35.63%

Return on Equity51.00%

Return on Assets23.54%

Miscellaneous

Outstanding Shares153,882,000

Market Cap$42.77 billion

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$277.91

-2.38 (-0.85 %)

(As of 01/15/2021 12:39 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIIB shares have decreased by 5.5% and is now trading at $278.18.
View which stocks have been most impacted by COVID-19.

Is Biogen a buy right now?

33 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 15 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Wednesday, October, 21st. The biotechnology company reported $8.84 EPS for the quarter, topping analysts' consensus estimates of $8.06 by $0.78. The biotechnology company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.34 billion. Biogen had a return on equity of 51.00% and a net margin of 35.63%. The company's revenue was down 6.2% compared to the same quarter last year. During the same quarter last year, the company posted $9.17 EPS.
View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen announced that its board has authorized a stock buyback program on Monday, December 23rd 2019, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's board believes its stock is undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided EPS guidance of 32.50-33.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $34.77. The company issued revenue guidance of $13.2-13.4 billion, compared to the consensus revenue estimate of $13.83 billion.

What price target have analysts set for BIIB?

33 equities research analysts have issued 12-month price objectives for Biogen's shares. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's share price to reach $306.13 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price.
View analysts' price targets for Biogen or view Wall Street analyst' top-rated stocks.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of BIIB's competitors.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Who are Biogen's key executives?

Biogen's management team includes the following people:

Mr. Michel Vounatsos, CEO & Director (Age 58, Pay $5.72M)
Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 63, Pay $1.99M)
Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 62, Pay $1.87M)
Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 54, Pay $1.32M)
Mr. Michael R. McDonnell, Exec. VP & CFO (Age 56)
Ms. Robin C. Kramer, VP & Chief Accounting Officer (Age 54)
Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 56)
Mr. Joe Mara, VP of Fin. & Head of Investor Relations
Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 52)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Gateway Investment Advisers LLC (0.04%), State of Alaska Department of Revenue (0.04%), Hexavest Inc. (0.03%), Traynor Capital Management Inc. (0.02%), 6 Meridian (0.02%) and Louisiana State Employees Retirement System (0.01%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Hexavest Inc., Cullinan Associates Inc., Sowell Financial Services LLC, Gateway Investment Advisers LLC, Arden Trust Co, Investment House LLC, and Cypress Capital Group. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Stephen A Sherwin.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Prairiewood Capital LLC, Traynor Capital Management Inc., OneAscent Financial Services LLC, NuWave Investment Management LLC, IFM Investors Pty Ltd, Strategic Investment Advisors MI, and KMG Fiduciary Partners LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $278.18.

How big of a company is Biogen?

Biogen has a market capitalization of $42.81 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here